Companies Will Partner to Provide Complete Supply Chain Solutions for the Life Science and Biopharmaceutical Industries

公司将合作为生命科学和生物制药行业提供完整的供应链解决方案

NASHVILLE, Tenn., Nov. 27, 2023 /PRNewswire/ -- Cryoport Inc. (Nasdaq: CYRX) ('Cryoport' or the 'Company'), a leading global provider of innovative products and services to the fast-growing cell and gene therapy industry enabling the future of medicine for a new era of life sciences, and NIPPON EXPRESS HOLDINGS, INC.

田纳西州纳什维尔，2023年11月27日/PRNewswire/--Cryoport Inc。（纳斯达克股票代码：CYRX）（'Cryoport'或'公司'），为快速增长的细胞和基因治疗行业提供创新产品和服务的领先全球供应商，为生命科学的新时代带来医学未来，日本快递控股公司。

('Nippon Express'), global logistics company, today announced a strategic partnership to provide temperature-controlled supply chain services for the life sciences industry on a global basis..

（'Nippon Express'）是全球物流公司，今天宣布建立战略合作伙伴关系，为全球生命科学行业提供温控供应链服务。。

Cryoport and Nippon Express will partner to design and implement comprehensive supply chain solutions to support each other's business efforts. The partnership will cover globally. This relationship brings together Nippon Express' industry-leading global logistics, with Cryoport Systems' fully integrated system, processes and equipment including its shipping packages, data solutions, biostorage and bioservices, and the ability to provide complete cell and gene therapy support services from upstream biomaterial collection to final delivery for dosing..

Cryoport和Nippon Express将合作设计和实施全面的供应链解决方案，以支持彼此的业务努力。伙伴关系将涵盖全球。这种关系汇集了Nippon Express的“行业领先的全球物流，Cryoport系统的全集成系统，流程和设备，包括其运输包，数据解决方案，生物存储和生物服务，以及从上游提供完整细胞和基因治疗支持服务的能力。生物材料收集到最终交付给药。。

Jerrell Shelton, Chief Executive Officer of Cryoport, commented, 'This partnership builds on our growing presence globally and bolsters our ability to service customers by benefiting from Nippon Express' industry-leading global network. As an organization, Cryoport is committed to enhancing its logistics solutions and adding new capabilities to support the life sciences.

Cryoport首席执行官Jerrell Shelton评论说：“这种合作关系建立在我们在全球日益增长的基础上，并通过受益于Nippon Express行业领先的全球网络来增强我们为客户提供服务的能力。作为一个组织，Cryoport致力于加强其物流解决方案，并增加支持生命科学的新能力。

Today's collaboration is the latest in a series of strategic partnerships to build greater value for our clients as we fulfill this mission.'.

今天的合作是一系列战略合作伙伴关系中的最新合作伙伴关系，旨在为我们的客户实现这一使命创造更大的价值。

Nippon Express added, 'We are excited to partner with Cryoport Systems, a recognized leader in providing temperature-controlled supply chain solutions. Working together we can leverage each other's complementary strengths to meet the rapidly growing demand in the life sciences and biopharmaceutical industries for a complete supply chain solution.'.

Nippon Express补充说：“我们很高兴与Cryoport Systems合作，Cryoport Systems是提供温控供应链解决方案的公认领导者。共同努力，我们可以利用彼此的互补优势，满足生命科学和生物制药行业快速增长的需求，从而实现完整的供应链解决方案。

About Cryoport, Inc.

关于Cryoport，Inc。

Cryoport, Inc. (Nasdaq: CYRX), is a global provider of innovative products and services to the fast-growing Cell & Gene Therapy industry - enabling the future of medicine for a new era of life sciences. With 48 strategic locations covering the Americas, EMEA (Europe, the Middle East and Africa) and APAC (Asia Pacific), Cryoport's global platform provides mission-critical bio-logistics, bio-storage, bio-processing, and cryogenic systems to the life sciences markets worldwide. .

Cryoport，Inc.（纳斯达克股票代码：CYRX）是为快速发展的细胞和基因治疗行业提供创新产品和服务的全球供应商，为生命科学的新时代创造医学的未来。Cryoport的全球平台拥有覆盖美洲，EMEA（欧洲，中东和非洲）和APAC（亚太地区）的48个战略地点，为生命科学市场提供关键任务的生物物流，生物存储，生物处理和低温系统全球。 .

For more information, visit www.cryoport.com or follow @cryoport on X, formerly known as Twitter at www.twitter.com/cryoport for live updates.

有关更多信息，请访问www.cryoport.com或访问X上的@cryoport，以前称为Twitter，网址为www.Twitter.com/cryoport，以便进行实时更新。

About Nippon Express

关于日本快递

Since its establishment in 1937, the NX Group has expanded its business from Japan to the world by contributing to the development of societies, linking people, companies, and communities through logistics. It has 739 bases in 312 cities in 49 countries and regions worldwide (as of the end of September 2023) and is expanding.  It has a long-term vision of becoming 'a logistics company with a strong presence in the global market' in 2037, the 100th anniversary of its founding..

自1937年成立以来，新新集团通过促进社会发展，通过物流将人，公司和社区联系起来，将业务从日本扩展到世界。它在全球49个国家和地区的312个城市拥有739个基地（截至2023年9月底），并且正在扩大。它的长期愿景是在成立100周年的2037年成为“在全球市场上占有一席之地的物流公司”。。

Forward-Looking StatementsStatements in this press release which are not purely historical, including statements regarding the Company's intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

前瞻性声明本新闻稿中并非纯粹历史性的陈述，包括关于公司意图，希望，信念，期望，陈述，预测，计划或未来预测的陈述，都是私人证券含义范围内的前瞻性陈述。1995年诉讼改革法。

These forward-looking statements include, but are not limited to, those related to the Company's industry, business, long-term growth prospects, including expected growth in all of the Company's markets, plans, strategies, acquisitions, future financial results and financial condition, such as the Company's outlook and guidance for full year 2023 revenue and the related assumptions and factors expected to drive revenue, projected growth trends in the markets in which the Company operates, the Company's plans and expectations regarding the launch of new products and services, such as the expected timing and benefits of such products and services launches, the Company's plans to further strengthen its business and continue to position itself for long-term and profitable growth in the cell and gene therapy industry, and anticipated regulatory filings or approvals with respect to the products of the Company's clients.

这些前瞻性陈述包括但不限于与公司行业，业务，长期增长前景相关的陈述，包括公司所有市场的预期增长，计划，策略，收购，未来财务结果和财务状况，例如公司对2023年全年收入的展望和指导以及预计将推动收入的相关假设和因素，公司经营市场的预计增长趋势，公司对新产品和服务推出的计划和期望，例如作为此类产品和服务的预期时间和收益，该公司计划进一步加强业务，并继续为细胞和基因治疗行业的长期有利可图的增长定位，并预计将对公司客户产品进行监管或批准。

It is important to note that the Company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic conditions, including as a result of the COVID-19 pandemic and its variants, supply chain constraints, inflationary pressures, the ongoing war between Russia and Ukraine and the effects of foreign currency fluctuations, t.

重要的是要注意，公司的实际结果可能与任何此类前瞻性声明中的结果有很大差异。可能导致实际结果大不相同的因素包括但不限于与经济状况变化相关的风险和不确定性，包括由于COVID-19大流行及其变种，供应链限制，通货膨胀压力，俄罗斯和乌克兰之间正在进行的战争以及外国货币波动的影响，t。

SOURCE Cryoport, Inc.

SOURCE Cryoport，Inc。